Nymox Pharmaceutical Corporation-Product Pipeline Review-2015

Nymox Pharmaceutical Corporation-Product Pipeline Review-2015


  • Products Id :- GMDHC07200CDB
  • |
  • Pages: 39
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Nymox Pharmaceutical Corporation-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Nymox Pharmaceutical Corporation-Product Pipeline Review-2015', provides an overview of the Nymox Pharmaceutical Corporation's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nymox Pharmaceutical Corporation's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Nymox Pharmaceutical Corporation including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Nymox Pharmaceutical Corporation's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Nymox Pharmaceutical Corporation's pipeline products

Reasons To Buy

Evaluate Nymox Pharmaceutical Corporation's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Nymox Pharmaceutical Corporation in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Nymox Pharmaceutical Corporation's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Nymox Pharmaceutical Corporation and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nymox Pharmaceutical Corporation

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Nymox Pharmaceutical Corporation and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Nymox Pharmaceutical Corporation Snapshot 5

Nymox Pharmaceutical Corporation Overview 5

Key Information 5

Key Facts 5

Nymox Pharmaceutical Corporation-Research and Development Overview 6

Key Therapeutic Areas 6

Nymox Pharmaceutical Corporation-Pipeline Review 8

Pipeline Products by Stage of Development 8

Pipeline Products-Monotherapy 9

Nymox Pharmaceutical Corporation-Pipeline Products Glance 10

Nymox Pharmaceutical Corporation-Late Stage Pipeline Products 10

Phase III Products/Combination Treatment Modalities 10

Nymox Pharmaceutical Corporation-Clinical Stage Pipeline Products 11

Phase II Products/Combination Treatment Modalities 11

Nymox Pharmaceutical Corporation-Early Stage Pipeline Products 12

Preclinical Products/Combination Treatment Modalities 12

Discovery Products/Combination Treatment Modalities 13

Nymox Pharmaceutical Corporation-Drug Profiles 14

NX-1207 14

Product Description 14

Mechanism of Action 14

R&D Progress 14

NXB-4221 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

NXC-4720 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

NXB-5886 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

NXT-1021 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

Nymox Pharmaceutical Corporation-Pipeline Analysis 20

Nymox Pharmaceutical Corporation-Pipeline Products by Route of Administration 20

Nymox Pharmaceutical Corporation-Pipeline Products by Molecule Type 21

Nymox Pharmaceutical Corporation-Recent Pipeline Updates 22

Nymox Pharmaceutical Corporation-Dormant Projects 32

Nymox Pharmaceutical Corporation-Discontinued Pipeline Products 33

Discontinued Pipeline Product Profiles 33

NX-1207 33

Nymox Pharmaceutical Corporation-Company Statement 34

Nymox Pharmaceutical Corporation-Locations And Subsidiaries 37

Head Office 37

Other Locations & Subsidiaries 37

Appendix 38

Methodology 38

Coverage 38

Secondary Research 38

Primary Research 38

Expert Panel Validation 38

Contact Us 38

Disclaimer 39

List of Tables

Nymox Pharmaceutical Corporation, Key Information 5

Nymox Pharmaceutical Corporation, Key Facts 5

Nymox Pharmaceutical Corporation-Pipeline by Indication, 2015 7

Nymox Pharmaceutical Corporation-Pipeline by Stage of Development, 2015 8

Nymox Pharmaceutical Corporation-Monotherapy Products in Pipeline, 2015 9

Nymox Pharmaceutical Corporation-Phase III, 2015 10

Nymox Pharmaceutical Corporation-Phase II, 2015 11

Nymox Pharmaceutical Corporation-Preclinical, 2015 12

Nymox Pharmaceutical Corporation-Discovery, 2015 13

Nymox Pharmaceutical Corporation-Pipeline by Route of Administration, 2015 20

Nymox Pharmaceutical Corporation-Pipeline by Molecule Type, 2015 21

Nymox Pharmaceutical Corporation-Recent Pipeline Updates, 2015 22

Nymox Pharmaceutical Corporation-Dormant Developmental Projects,2015 32

Nymox Pharmaceutical Corporation-Discontinued Pipeline Products, 2015 33

Nymox Pharmaceutical Corporation, Subsidiaries 37

List of Figures

Nymox Pharmaceutical Corporation-Pipeline by Top 10 Indication, 2015 7

Nymox Pharmaceutical Corporation-Pipeline by Stage of Development, 2015 8

Nymox Pharmaceutical Corporation-Monotherapy Products in Pipeline, 2015 9

Nymox Pharmaceutical Corporation-Pipeline by Top 10 Route of Administration, 2015 20

Nymox Pharmaceutical Corporation-Pipeline by Top 10 Molecule Type, 2015 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Nymox Pharmaceutical Corporation; Nymox Pharmaceutical Corporation - Key Therapeutics; Nymox Pharmaceutical Corporation - Pipeline Overview and Promising Molecules; Nymox Pharmaceutical Corporation - News; Nymox Pharmaceutical Corporation - Latest Updates; Nymox Pharmaceutical Corporation - Pipeline; Nymox Pharmaceutical Corporation - Discontinued/Dormant Projects

select a license

Single User License
USD 1500 INR 97170
Site License
USD 3000 INR 194340
Corporate User License
USD 4500 INR 291510

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com